Aspen Aerogels Inc

ASPN remains in a Stage 4 decline with a clear sequence of lower highs and lower lows, reinforced by downward-sloping EMAs and resistance at the 50 and 200 SMAs. Medium-term bias stays bearish, and short-term execution reads as neutral with price oscillating around flat/declining EMAs below major moving averages. We defer bearish execution, looking to trim into rallies toward the 9/21 EMA and the SMA 50/200 resistance zones.

• ↑Q3 revenue guidance of $65–80M implies 30–60% QoQ growth.
• ↑Q2 revenue rose 32% QoQ to $49.8M amid LNG demand.
• ↓GAAP net loss widened to $23.3M in Q2, eroding profitability.